Aducanumab - Biogen

Drug Profile

Aducanumab - Biogen

Alternative Names: Anti-beta amyloid monoclonal antibody - Biogen Idec; BART; BIIB 037; NI-10

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 24 Jul 2018 Biogen completes enrolment in its phase III ENGAGE and EMERGE trials for Alzheimer's disease (Early stage disease)
  • 01 May 2018 Biogen exercises its option to reduce the negotiated royalty rates payable on potential future sales of aducanumab
  • 15 Mar 2018 Safety data from the long-term extension phase Ib PRIME study in Alzheimer's disease released by Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top